Conference Abstract | Volume 9 (ConfProc7): Abstract 132 | Published:  29 Oct 2026

Evaluation of AEFI system in the Eastern Region, Ghana, 2020 - 2024

Peter Kofi Alordji1,2,&, Rita Asante1,2 Samuel Sackey2, Ernest Kenu2

1Food and Drugs Authority, Accra, Ghana, 2Ghana Field Epidemiology and Laboratory Training Program, Accra Ghana

&Corresponding author: Peter Kofi Alordji, Food and Drugs Authority, Accra, Ghana, Email: peter.alordji@fda.gov.gh

Received: 29 Aug 2025, Accepted: 28 Oct 2025, Published: 29 Oct 2026

Domain: Infectious Disease Epidemiology

This is part of the Proceedings of the 8th Ghana FELTP Scientific Conference and FELTP Competency Graduation, Accra, Ghana, 10 – 11 December, 2025

Keywords: Adverse Events Following Immunisation, Public Health

©Peter Kofi Alordji et al. Journal of Interventional Epidemiology and Public Health (ISSN: 2664-2824). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Peter Kofi Alordji et al. Evaluation of AEFI system in the Eastern Region, Ghana, 2020 – 2024. Journal of Interventional Epidemiology and Public Health. 2026;9(ConfProc7):132. https://doi.org/10.37432/JIEPH-CONFPRO7-00132

Introduction

Adverse Events Following Immunisation (AEFIs) remain a global concern. The AEFI surveillance helps to monitor the safety of vaccines and immunisation post-licensure and respond to safety concerns. The Eastern Region has seen a decline from 61% to 31.6% in case reporting between 2022 and 2023. We evaluated the AEFI surveillance system in the Eastern Region to determine if its objectives are being met, to assess its attributes and usefulness for policies in protecting public health.

Methods

A descriptive cross-sectional study was used to evaluate the surveillance system from 2020 to 2024. Globally accepted guidelines, the Centres for Disease Control and Prevention (CDC) updated guidelines for evaluating public health surveillance, 2001, was used to evaluate the system. Records were also reviewed. Microsoft Excel, 2016 was used to analyse data into frequencies, proportions and results presented as text, tables and charts.

Results

About 664 AEFI cases, including 30 (4.5%) serious cases, were reported within the study period. High case detection rate of 10.3% AEFIs per 100,000 surviving population was recorded in 2024. Reporting forms were modified to accommodate ages >60years and details on pregnant and lactating women. Most, 84.8% (28/33), of the administrative districts in the region were represented in the AEFI reports.

Conclusion

The system is useful in estimating magnitude of morbidity of AEFIs and improving clinical practices. The system was flexible and stable, with a sensitive case definition. Acceptability, timeliness and simplicity were fair, with poor representativeness and data quality. We recommend an increase in public sensitization and staff training on tools used for AEFI reporting and data management. A follow up to ensure public health action is implemented will be required.

 

Menu

Keywords

  • Adverse Events Following Immunisation
  • Public Health
Views: 128